Salud financiera de hoja de balance de SI-BONE

Salud financiera controles de criterios 6/6

SI-BONE tiene un patrimonio de los accionistas total de $165.0M y una deuda total de $36.2M, lo que sitúa su ratio deuda-patrimonio en 21.9%. Sus activos y pasivos totales son $227.0M y $62.0M respectivamente.

Información clave

21.9%

Ratio deuda-patrimonio

US$36.19m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$150.82m
Patrimonio	US$164.97m
Total pasivo	US$62.02m
Activos totales	US$227.00m

Actualizaciones recientes sobre salud financiera

Recent updates

Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues

Nov 04

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Sep 25

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

Apr 01

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

Feb 29

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Feb 28

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Nov 12

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Aug 09

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

Apr 20

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Jan 01

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Sep 24

SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?

Apr 19

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Jan 05

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Oct 05

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($203.7M) de SIBN superan a sus pasivos a corto plazo ($24.7M).

Pasivo a largo plazo: Los activos a corto plazo de SIBN ($203.7M) superan a sus pasivos a largo plazo ($37.3M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: SIBN tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de SIBN ha pasado de 56.8% a 21.9% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: SIBN tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: SIBN dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 6.2% cada año

Salud financiera de hoja de balance de SI-BONE

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Recent updates

SI-BONE, Inc. Updates Financial Guidance for the Year 2024

Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues

SI-BONE, Inc. to Report Q3, 2024 Results on Nov 12, 2024

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc. Revises Financial Guidance for 2024

SI-BONE, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Si-Bone, Inc. Increases Revenue Guidance for 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

SI-BONE, Inc., Annual General Meeting, Jun 25, 2024

SI-BONE, Inc. to Report Q1, 2024 Results on May 06, 2024

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

New minor risk - Profitability

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

SI-BONE, Inc. Provides Earnings Guidance for the Year 2024

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Forecast to breakeven in 2026

CEO & Director recently sold US$809k worth of stock

SI-BONE, Inc. to Report Q4, 2023 Results on Feb 26, 2024

SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

Forecast to breakeven in 2026

SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Lead Independent Director notifies of intention to sell stock

Executive Chairman recently sold US$141k worth of stock

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Price target decreased by 7.3% to US$28.38

SI-BONE, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Executive Chairman exercised options and sold US$337k worth of stock

SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera 5.5/6.0 System Rods

Executive Chairman notifies of intention to sell stock

CEO & Director recently sold US$189k worth of stock

Executive Chairman notifies of intention to sell stock

Independent Director recently sold US$616k worth of stock

SI-BONE, Inc. Revises Revenue Guidance for the Year 2023

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SI-BONE, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO & Director recently sold US$224k worth of stock

President of Commercial Operations notifies of intention to sell stock

Executive Chairman exercised options and sold US$5.1m worth of stock

SI-BONE, Inc. has completed a Follow-on Equity Offering in the amount of $83.05 million.

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Key Executive notifies of intention to sell stock

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 16% to US$24.50

President of Commercial Operations notifies of intention to sell stock

CEO & Director recently sold US$226k worth of stock

Executive Chairman notifies of intention to sell stock

SI-BONE, Inc. to Report Q4, 2022 Results on Feb 27, 2023

SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite(R) Implant System

Price target decreased to US$22.38

Executive Chairman recently sold US$105k worth of stock

CEO & Director notifies of intention to sell stock

Third quarter 2022 earnings: EPS exceeds analyst expectations

SI-BONE, Inc. Updates Revenue Guidance for the Year 2022

SI-BONE, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Executive Chairman recently sold US$138k worth of stock

SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022